Oxford-AstraZeneca promised its COVID-19 vaccine would be effective, cheap and available worldwide. Five months after its launch, the path forward has been anything but smooth.
The Danish Health Authority said it will continue its vaccination campaign without the shot made by AstraZeneca, but said its benefits outweigh the risks for those who do get it.
One of the hottest areas of research right now: studies to determine how well current vaccines work against emerging coronavirus "variants of concern."
The European Medicines Agency said Wednesday that blood clots should be listed as a possible but rare side effect of the AstraZeneca COVID-19 vaccine, stressing the shot's benefits outweigh the risks.
Some Mexicans with family ties or dual citizenship in the U.S., or who can afford the airfare, head north of the border to get vaccinated faster than the months of waiting for one back home.
The German chancellor announces an intensified coronavirus lockdown going into Easter, warning that new mutations raise the specter of a potentially deadly "third wave" of COVID-19.
In an unusual post-midnight statement, the National Institute of Allergy and Infectious Diseases said AstraZeneca might have used old data for its COVID-19 vaccine trial.
"Its benefits continue to be far greater than its risks," said Dr. Sabine Straus of the agency's risk committee. It found no increase in the overall risk of blood clots with the vaccine.
NPR tours the factory of the world's largest vaccine maker: Serum Institute of India. It's manufacturing nearly 100 million doses a month of the Oxford-AstraZeneca formula and exporting them globally.
Ireland has temporarily suspended use of the COVID-19 vaccine made by AstraZeneca following reports that several people developed blood clots after receiving the shot.
The Prime Minister of Trinidad and Tobago gave an impassioned speech about the vaccine rollout, warning of hoarding and price gouging. Here's what we could find out about the cost of a dose.
For low- and middle-income countries, just obtaining doses has been a challenge. And now concerns are being raised about the effectiveness of the more affordable AstraZeneca option.
European Commission President Ursula von der Leyen announced Sunday that AstraZeneca would also deliver the vaccines one week earlier than originally scheduled.
"The companies must deliver. They must honor their obligations," the European Commission's president said after both AstraZeneca and Pfizer said they were experiencing shipping issues.
Almost 150,000 people in India have died from complications of COVID-19, behind only the U.S. and Brazil. India plans to begin inoculating its population of 1.4 billion this month.
The company had placed its worldwide vaccine trials on hold for several days. It now says a safety review by regulators and reviewers is complete. No word on when studies in the U.S. might resume.
